Big biotech stocks like Alexion Pharmaceuticals (NASDAQ:ALXN) and Regeneron (NASDAQ:REGN) have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have impressed investors and Wall Street. Regeneron and Alexion look like winners heading forward, but which company -- and stock -- is on the best track for long-term growth?

Alexion's grown famous for Soliris, its orphan drug that's the most expensive in the world. Soliris isn't just a pricey therapy, however; it's also an unstoppable blockbuster, reaping more than $1.5 billion in sales last year at growth of 37% year over year. Analysts think Alexion's top drug has plenty more room to run, but big biotech peer Regeneron has a star drug of its own. Regeneron'seye therapy Eylea has taken the biotech world by storm over the past year, reaping more than $1.8 billion in global sales last year and on pace to pick up more revenue this year.

Both companies have developing programs in their pipelines as well, but which stock is more worthy of your investment? Find out in the video below, as Motley Fool contributor Dan Carroll takes you through the ins and outs of these two soaring stocks and their standout drugs -- and which one's set up for the best growth in the future.

Biotech isn't theĀ only place for investors to find hyper-growth stocks
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Dan Carroll has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.